Pathway Genomics announced today the launch of BRCATrue, a next-generation sequencing test that looks for mutations in BRCA1 and BRCA2, genes associated with breast and ovarian cancer. Along with the new test, the company also announced an accompanying One for One program to help people in need. Similar to the One for One program TOMS Shoes offers, in which the company donates a pair of shoes for every pair purchased, Pathway’s program will donate one BRCATrue test for every test ordered.
Working with patient advocacy groups such as Susan G. Komen, Bright Pink, and the National Ovarian Cancer Coalition, Pathway Genomics will donate up to $10 million of free testing through the two-year program. The BRCATrue test, which is covered by insurance and has a two-week turnaround time for results, costs $1,799. In addition to the One for One program, Pathway also offers a financial assistance program that patients can discuss with their physicians or with Pathway’s billing department directly.
Ardy Arianpour, Pathway Genomics’ chief strategy officer, says BRCATrue is just the first of many genetic cancer tests the company plans to announce this year.
To discuss your own hereditary risk assessment, consult your physician, or call 877-505-7374 to speak to a Pathway Genomics genetic counselor.